Advertisement

Reactions Weekly

, Volume 1739, Issue 1, pp 197–197 | Cite as

Oxcarbazepine/sodium phenylbutyrate interaction

Elevated level of active or effective form of sodium phenylbutyrate: 2 case reports
Case report
  • 17 Downloads

Author InformationDrug interaction

In a case series, two children [one boy and one girl; exact ages at the time of reactions onset not stated] were described, who showed elevated level of active or effective form of sodium phenylbutyrate [time to reactions onset not stated] during concomitant administration of oxcarbazepine and sodium phenylbutyrate [4-phenylbutyrate] for progressive familial intrahepatic cholestasis type 2 (PFIC2).

Patient A: At the time of report, the boy was 12 years old. He had physiologic jaundice during his neonatal period. At 3 months of age, he developed a bleeding diathesis and a suspicion of PFIC2 was made based on the various liver tests. He was irritable throughout infancy and began scratching himself by a year of age and his subsequent course became dominated by intractable severe pruritus. This scratching led to multiple and frequent impetiginized excoriations and episodes of cellulitis requiring antimicrobial therapy [specific drug not stated]. Attempts...

Reference

  1. Malatack JJ, et al. A Drug Regimen for Progressive Familial Cholestasis Type 2. Pediatrics 141: No. 1, Jan 2018. Available from: URL: http://doi.org/10.1542/peds.2016-3877 - USA

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations